SRX Global to Acquire CERo Therapeutics, a Company Developing CER 1236 for Hematologic Malignancies

Chief Executive Officer of SRX Global Inc., Kent Cunningham stated, “This proposed acquisition reflects our strategy of investing in high-conviction operating companies with meaningful long-term value creation potential. CERo’s differentiated approach to engineered T cell therapeutics, and the clinical progress the team has made with CER-1236, make it a compelling addition to our platform. We expect this transaction to give CERo enhanced access to capital and broader operational resources to support continued advancement of CER-1236 and its broader R&D efforts, while providing SRX shareholders exposure to an innovative oncology asset.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib